[Klinefelter's syndrome diagnosed at the onset of acute myeloid leukemia with inv (16) following treatment for germ cell tumor].


Journal

[Rinsho ketsueki] The Japanese journal of clinical hematology
ISSN: 0485-1439
Titre abrégé: Rinsho Ketsueki
Pays: Japan
ID NLM: 2984782R

Informations de publication

Date de publication:
2022
Historique:
entrez: 4 8 2022
pubmed: 5 8 2022
medline: 6 8 2022
Statut: ppublish

Résumé

A 22-year-old man with a history of mediastinal germ cell tumor, which was diagnosed at age 20 and remained disease-free after chemotherapy, was diagnosed with acute myeloid leukemia (AML) M2 in January 2020. Karyotype analysis of bone marrow (BM) specimen at diagnosis detected 47,XXY, inv (16) in all cells. Following induction treatment, he achieved complete remission with a remarkable decrease in the minimal residual disease marker. Although considered related to therapy, the AML had a prognostically favorable karyotype, and the initial treatment response was very good. He had no human leukocyte antigen-matched sibling donor candidate. Thus, allogeneic hematopoietic stem cell transplantation was not scheduled at the first complete remission. After three cycles of consolidation therapy, he remained disease-free for over one year. Karyotype analysis of BM during remission revealed that all analyzed cells harbored 47,XXY, and Klinefelter syndrome (KS) was diagnosed. Although the patient experienced an adjustment disorder on KS diagnosis, he had overcome the difficulty with the assistance of psycho-oncologists, clinical psychologists, and genetic counselors. Herein, we report this rare case of KS that manifested after AML diagnosis following mediastinal germ cell tumor treatment.

Identifiants

pubmed: 35922942
doi: 10.11406/rinketsu.63.746
doi:

Types de publication

Case Reports Journal Article

Langues

jpn

Sous-ensembles de citation

IM

Pagination

746-752

Auteurs

Kisa Tanabe (K)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Yuho Najima (Y)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Takuhiko Inokuchi (T)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Mae Endo (M)

Department of Psycho-oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Yuko Nishio (Y)

Department of Psycho-oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Daichi Sadato (D)

Clinical Research Support Center, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Yasuhiro Kanbara (Y)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Yuya Atsuta (Y)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Ryosuke Konuma (R)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Hiroto Adachi (H)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Atsushi Wada (A)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Yuya Kishida (Y)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Yusuke Uchibori (Y)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Yuma Noguchi (Y)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Junichi Mukae (J)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Naoki Shingai (N)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Takashi Toya (T)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Noriaki Shimizu (N)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Takeshi Kobayashi (T)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Hironori Harada (H)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
Laboratory of Oncology, Tokyo University of Pharmacy and Life Sciences.

Hisashi Sakamaki (H)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Kazuteru Ohashi (K)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Yuka Harada (Y)

Clinical Research Support Center, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Tatsuro Yamaguchi (T)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Nobuya Akizuki (N)

Department of Psycho-oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Noriko Doki (N)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH